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Optimal Treatment for Hemodialysis Patients with Critical Limb Ischemia;
Comparison Surgical and Endovascular Revascularization for Infrainguinal
Artery Disease
Tatsuya Shiraki,1 Osamu Iida1
1Kansai Rosai Hospital, Japan
BACKGROUND The number of patients on hemodialysis complicated
with critical limb ischemia (CLI) is increasing worldwide. Latest
guideline points to life expectancy of <2 years as main determinant in
revascularization modality selection (bypass surgery [BSX] or endo-
vascular therapy [EVT]) in patients with critical limb ischemia (CLI).We
compared clinical outcomes after EVT and after BSX, and examined
predictors of 2-year mortality after revascularization in this setting.
METHODS This is retrospective multicenter study. From 2007 to
2009, 246 consecutive CLI patients on hemodialysis (age, 6910 years;
70% male; 45%non-ambulatory status; 69% diabetics; 21% with rest
pain; and 79% with tissue loss) who underwent revascularization for
infrainguinal lesions (178 EVT and 68BSX) were enrolled. Two-year
amputation-free survival (AFS), overall survival (OS), major amputa-
tion (MA), and major adverse limb event (MALE: repeat EVT, surgical
reconstruction, major amputation) were evaluated by Kaplan-Meier
analysis. Predictors for 2-year mortality after revascularization were
determined using a Cox hazards model.
RESULTS Two-year AFS, OS, MA, and MALE rates were not signiﬁ-
cantly different between EVT and BSX (60% vs. 52%, P¼0.20; 80% vs.
69%, P¼0.18; 15% vs. 18%, P¼0.36; and 49% vs.42%, P¼0.40,
respectively), which held after adjustment with covariates. However,
death within 30 days was signiﬁcantly higher after BSX than EVT
(P¼0.048). Predictors of 2-year mortality after EVT or BSX were age
>75(hazard ratio [95% conﬁdence interval], 1.79 [1.09-2.93]), and
albumin<3g/dL (2.09 [1.21-3.59]).
CONCLUSION After revascularization in CLI patients on hemodialysis,
death ratewithin 30 dayswas higher in BSX than EVT; AFS, OS,MA, and
MALE rates were not signiﬁcantly different between EVT and BSX;
older age and low albumin level were associated with 2-year mortality.
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Catheter-Based Renal Denervation Could Lower Blood Pressure As Early
As One Month
Chuan Lei Chao,1 Po-Lin Lin,2 Tsung Yeh Yang,1 Chun-Wei Lee,1
Ying-Hsiang Lee1
1MacKay Memorial Hospital, Taiwan; 2MacKay Memorial Hospital,
Hsinchu, Taiwan
BACKGROUND Catheter-based renal sympathetic denervation (RDN)
has been shown to reduce blood pressure (BP) in resistant hyperten-
sion. Cohort of Symplicity HTN-3 study revealed discrepancy of
response between races. Our study was aimed to determine its efﬁ-
cacy in Taiwanese population.
METHODS Patients who received RDN and had ofﬁce BPat baseline, 3,
6 and 12 months after treatment were enrolled. Ambulatory 24-
hourBP monitoring (ABPM) and ofﬁce BP at 1 month was also
reviewed if available. Post procedure BP was compared to baseline.
Number and location of ablation under ﬂuoroscope were documented
to determine its impact on BP lowering.
RESULTS 72 patients (mean age 5711 years, 67% of male) had base-
line ofﬁce systolic BP 1682 mmHg, diastolic BP 9319 mmHg and
mean of 4.60.1 antihypertension medications. 1 patient had major
complication of vascular access hemorrhage without further sequelae.
Post procedure ofﬁce BPs were reduced by 21/5, 26/9, 23/9 mmHg at 3,
6, and 12 months (P<0.05), respectively. Among 36 patients with
ofﬁce BP at 1 month, 29 (81%) had >10mmHg of BP change and 22
(61%) had >20 mmHg. The response rate was seen persistently at 6
month. Fewer number of ablation was with less reduction in BP.
CONCLUSION For resistant hypertension, catheter-based sympa-
thetic RDN could achieve substantial reduction in BP. The efﬁcacy
could be seen as early as one month.
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Who Are the Patients That Improved Cardiac Function in Acute Heart
Failure with Reduced LV EF?
Song-Yi Kim,1 Joon Hyouk Choi,1 Ki-Seok Kim,1 Seung-Jae Joo1
1Jeju National University Hospital, Korea (Republic of)BACKGROUND Recovery of LV EF is the goal of treatment in HF with
reduced EF. We thought that patients with HF who recovered LV
function (HF-recovered) have different characteristics. We sought to
characterize the HF-Recovered population and their prognosis.
METHODS We enrolled 227 patients with AHF with reduced EF who
were residents of Jeju Island from 2005 to 2013. They were divided
into two groups; HF-recovered (F/U EF 50% but initial EF
was <50%,N¼40, 17.6%). and HF with reduced EF (HFrEF, Initial and
F/U EF were both<50%, N¼187, 82.4%). Clinical characteristics and
laboratory ﬁndings were reviewed from medical records. They were
followed at least 2yrs. Clinical end-points were death or readmission
due to congestive HF (CHF).
RESULTS HF-recovered group were younger (63.615.57 vs.
73.4  13.57,p<0.001), and they had lower peak CKMB(5.64.64
vs.19.7966.58, p¼0.038), troponin-T (0.050.13 vs. 0.780.06,
p¼0.008) and proBNP level (5091.64876.5 vs. 8486.1  8884.9,
p¼0.002). In HF-Recovered group, most common etiology of HF was
dilated cardiomyopathy (N¼13, 32.5%). On the other hand, that was is
chemic heart disease in HFrEF group (N¼89, 47.6%) HF-recovered
patients also had a lower prevalence of coronary artery disease
requiring revascularization and consequently fewer with an ischemic
origin than HF-REF. Prevalence of hypertension, DM, CKD were
similar in both groups. 1-year survival rate of HF-recovered group was
signiﬁcant higher than HFrEF group (97.5% vs. 85.5%, p¼0.039), but
2-year survival rate was not different from that of HFrEF (90% vs.
79.6%, p¼0.113). 2-year CHF-free survival rate was not different in
both groups (70% vs. 67%, p¼0.634).
CONCLUSION In the patients of AHF with reduced EF, small portion
of patients had recovery of LV function. HF-recovered patients are
younger and associated with a better cardiac biomarker proﬁle. Their
etiology of HF was non-ischemic.
Their short-termprognosis were better than those of HFrEF patients,
but mid-term prognosis were similar.
TRANSRADIAL INTERVENTION
(TCTAP A-177 TO TCTAP A-178)
TCTAP A-177
Multi-Slice Computed Tomography Coronary Angiography for Detection of
Coronary Anomalies
Xuguang Qin1
1Hospital of Tsinghua University, China
BACKGROUND Congenital coronary artery anomaly occurs infre-
quently in general population, and they are present at birth, but
relatively few are symptomatic during childhood. Most coronary
anomalies are discovered as incidental ﬁndings during coronary
angiography. Their clinical relevance varies widely. They may be
clinically silent and totally benign, or may cause many adverse clinical
events and even sudden cardiac death resulting insigniﬁcant
morbidity and mortality, even among young adults.1, 2Cardiac cathe-
terization has traditionally been indicated to demonstrate the coro-
nary vasculature in detail and has remained the reference standard
imaging modality. Owing to the potentially complex three dimen-
sional anatomy of the coronary anomaly, conventional angiography,
not infrequently, incompletely delineates the anatomical course of
the coronary anomaly (3). This study sought to determine the ability
of MSCT to detect the origin and course of anomalous coronary artery.
METHODS From January 2007 to September 2010, we enrolled 16
consecutive patients primarily with suspected coronary artery disease
